

To,

Date: 29.06.2021

1. BSE Limited P.J. Towers, Dalal Street, Mumbai – 400001	2. Metropolitan Stock Exchange of India Limited Vibgyor Towers, 4 th floor, Plot No. C62, Opp. Trident Hotel, BandraKurla Complex, Bandra (E), Mumbai- 400098
---	---

Dear Sir/Madam,

Sub: Outcome of board meeting held on 29.06.2021

Ref: (Scrip code: 539267/ DRHABEEB)

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Dr Habeebullah Life Sciences Limited held on Tuesday, the 29th day of June, 2021 at 3:30 p.m. at the registered office of the Company, the following were considered and approved by the Board:

1. Audited financial results (Standalone & Consolidated) for the quarter and year ended 31.03.2021.
2. Audit Report (standalone & consolidated) along with Declaration as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for year ended 31.03.2021.
3. Termination of Collaboration Agreement (CA) between Centre for Liver Research and Diagnostics (CLRD) and Dr Habeebullah Life Sciences Limited (DHLSL).
4. Appointment of Ms. Aakanksha Shukla as Additional Director (Independent Category) of the Company.
5. Appointment of Mr. Y. Rama Mohan Reddy as Additional Director (Independent Category) of the Company.
6. Resignation of Mohammad Aejaaz Habeeb as Director of the Company.
7. Resignation of Ameer Basha Paspala as Director of the Company.
8. Resignation of Ms. Akka Jyothy as Independent Director of the Company.
9. Resignation of Mr. T.V Ramakrishna as Independent Director of the Company.
10. Reconstitution of the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee.



Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

Regd. Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad-500048. TS. India.

Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad-500008. TS. India.

CIN No.: L85110TG1996PLC099198. Email: cs@drhsl.com, info@drhsl.com,
pcproductsindia@gmail.com Contact No.: 040 - 2970 3333, +91 9030057370.

Disclosure as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 with regard to appointment or resignations as mentioned above is enclosed hereunder.


The meeting concluded at 5:00 p.m.

This is for the information and records of the Exchange, please.

Thanking you.

Yours Sincerely,

For Dr Habeebullah Life Sciences Limited



K. Krishnam Raju
Chairman & Whole-Time Director
(DIN: 00874650)

Encl: as above



Dr Habeebullah Life Sciences Limited
(Formerly Known as PC Products India Limited)


Regd. Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad-500048. TS. India.

Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad-500008. TS. India.

CIN No.: L85110TG1996PLC099198. Email: cs@drhlsl.com, info@drhlsl.com,
pcproductsindia@gmail.com **Contact No.:** 040 - 2970 3333, +91 9030057370.

Disclosure as per Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 with regard to appointment or resignations as mentioned above is enclosed hereunder.

S.No.	Particulars	Aakanksha Shukla	Y. Rama Mohan Reddy	Akka Jyothy	T.V Ramakrishna
1.	Reason for change viz appointment, resignation	Appointment	Appointment	Resignation	Resignation
2.	Date of appointment/Cessation	29.06.2021	29.06.2021	29.06.2021	29.06.2021
3.	Term of Appointment	5 years subject to the approval of Members	5 years subject to the approval of Members	NA	NA
4.	Brief profile (in case of Appointment)	She is a commerce graduate and a Company Secretary by Profession. She has worked as a Company Secretary of listed companies for two years after qualification and then started her own practice at the age of 27 years. She is currently a PCS and have a reasonably good clientele including listed, unlisted private and public companies and government companies. she specialize in compliances relating to preferential allotment of shares of listed and unlisted companies, mergers, IPO and buy back of shares	He is a B.com Graduate and has more than 25 years of rich experience in the field of Management, Marketing and Administration.	NA	NA
5.	Relationship with other directors (in case of Appointment)	NIL	NIL	NIL	NIL



Dr Habeebullah Life Sciences Ltd
(Formerly Known as PC Products India Limited)

Regd. Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad-500048. TS. India.

Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad-500008. TS. India.

CIN No.: L85110TG1996PLC099198. Email: cs@drhsl.com, info@drhsl.com,
pcproductsindia@gmail.com **Contact No.:** 040 - 2970 3333, +91 9030057370.

S.No.	Particulars	Mohammad Aejaz Habeeb	Ameer Basha Paspala
1.	Reason for change viz appointment, resignation	Resignation	Resignation
2.	Date of appointment/Cessation	29.06.2021	29.06.2021
3.	Term of Appointment	NA	NA
4.	Brief profile (in case of Appointment)	NA	NA
5.	Relationship with other directors (in case of Appointment)	NIL	NIL

79



(Formerly Known as PC Products India Limited)

Regd. Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad-500048. TS. India.

Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad-500008. TS. India.

CIN No.: L85110TG1996PLC099198.

Email: cs@drhlsl.com, info@drhlsl.com

pcproductsindia@gmail.com **Contact No.:** 040 - 2970 3333, +91 9030057370.

PART II - STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER IV AND YEAR ENDED 31ST MARCH, 2021

(INR In Lakhs)

Particulars		STANDALONE FINANCIALS				
		Quarter Ended			Year Ended	
		3 Months Ended 31/03/2021	Preceeding 3 Months Ended 31/12/2020	Corp. 3 months ended 31/03/2020	3/31/2021	3/31/2020
		Audited	Unaudited	Audited	Audited	Audited
I	Revenue from Operations	-	-	24.20	1.30	143.19
II	Other Income	3.85	3.74	5.20	14.77	15.82
III	Total Revenue (I+II)	3.85	3.74	29.40	16.07	159.01
IV	Expenses					
	Cost of Material Consumed	-	-	3.03	0.19	22.49
	Employee benefits expense	0.78	7.52	41.99	33.17	125.96
	Depreciation and Amortisation expense	0.17	0.26	0.37	0.96	1.08
	Other Expenses	5.01	14.09	25.97	58.72	198.49
	Total Expenses	5.96	21.87	71.36	93.04	348.02
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(2.11)	(18.13)	(41.96)	(76.97)	(189.01)
VI	Exceptional Items	-	-	-	-	-
VII	Profit/(Loss) before tax (V-VI)	(2.11)	(18.13)	(41.96)	(76.97)	(189.01)
VIII	Tax Expense:					
	Current Tax	-	-	-	-	-
	Deferred Tax	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(2.11)	(18.13)	(41.96)	(76.97)	(189.01)
X	Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)					
XIII	Profit/ (Loss) for the period (IX+XII)	(2.11)	(18.13)	(41.96)	(76.97)	(189.01)
XIV	Other Comprehensive Income					
	A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss					
	(B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss	12.67	-	1.85	14.08	1.85
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	10.56	(18.13)	(40.11)	(62.89)	(187.16)
XVI	Comprehensive Income attributable to Non Controlling Interest	-	-	-	-	-
XVII	Comprehensive Income attributable to Owners of the company	10.56	(18.13)	(40.11)	(62.89)	(187.16)
XVIII	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)					
	1) Basic	0.07	(0.12)	(0.27)	(0.42)	(1.28)
	2) Diluted	0.07	(0.12)	(0.27)	(0.42)	(1.28)
XIX	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)					
	1) Basic	-	-	-	-	-
	2) Diluted	-	-	-	-	-
XX	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)					
	1) Basic	0.07	(0.12)	(0.27)	(0.42)	(1.28)
	2) Diluted	0.07	(0.12)	(0.27)	(0.42)	(1.28)
XXI	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1,480.87	1,480.87	1,480.87	1,480.87




Notes:

1. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been audited by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on Tuesday, June 29th, 2021.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
4. The figures of the current quarter ended March 31, 2021 and the quarter ended March 31, 2020 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.
5. The Company has only one reportable segment i.e., **Heath Care** Sector. Hence, the separate disclosure on Segment information is not required.
6. The results are also available on the webiste of the Company www.drhsl.com

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K Krishnam Raju
Executive Chairman(DIN 00874650)




Place : Hyderabad
Date: 29/06/2021

DR Habeebullah Life Sciences Limited

Standlone Statement of Assets and Liabilities

(INR. in Lakhs)

Particulars	STANDALONE	
	31/03/2021	31/03/2020
ASSETS		
1 Non Current Assets		
a Property, Plant and Equipments	1.79	2.74
b Capital Work In Progress	-	-
c Investment Prpoerty	-	-
d Goodwill	-	-
e Other Intangible Assets	-	-
f Intangible Assets under development	-	-
g Biological assets other than bearer plants	325.95	303.23
h Financial Assets:	-	-
i Investments	487.06	487.06
ii Trade Receivables	-	-
iii Loans	-	-
iv Others	203.99	204.28
v Loans	-	-
vi Others	-	-
i Deferred Tax Assets (net)	-	-
j Other Non Current Assets	-	-
Total Non Current Assets	1,018.79	997.30
2 Current Assets		
a Inventories	12.92	13.11
b Financial Assets	-	-
i Investments	-	-
ii Trade Receivables	214.26	217.51
iii Cash and Cash Equivalents	0.41	2.35
iv Bank balances other than above	-	-
v Loans and Advances	134.00	134.00
vi Other financial assets	37.77	24.10
c Current Tax Assets (net)	-	-
d Other Current Assets	304.39	304.31
Total Current Assets	703.75	695.40
Total Assets	1,722.53	1,692.70
EQUITY AND LIABILITIES		
1 Equity		
a Equity Share Capital	1,480.87	1,480.87
b Other Equity	-	-
i Share Warrants	-	-
ii Reserves and Surplus	(300.83)	(237.94)
iii Non-Controlling Interests	-	-
Total - Equity	1,180.04	1,242.93




2 Liabilities		
Non Current Liabilities		
a Financial Liabilities	-	-
i Borrowings	-	-
ii Trade Payables	-	-
iii Other Financial Liabilities	-	-
b Provisions	4.56	14.50
c Deferred Tax Liabilities (net)	-	-
d Other Non Current Liabilities	-	-
Total Non Current Liabilities	4.56	14.50
Current Liabilities		
a Financial Liabilities		
i Borrowings	234.05	179.15
ii Trade Payables	28.72	30.50
iii Other Financial Liabilities	-	-
b Other Current Liabilities	275.15	223.20
c Provisions	0.00	2.43
d Current Tax Liabilities (net)	-	-
Total Current Liabilities	537.93	435.28
Total - Equity and Liabilities	1,722.53	1,692.70

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju
Executive Chairman (DIN 00874650)



Place: Hyderabad
Date: 29/06/2021

PART II - CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER IV AND YEAR ENDED 31ST MARCH, 2021

(INR In Lakhs)


Particulars	CONSOLIDATED FINANCIALS				
	Quarter Ended			Year Ended	
	3 Months Ended 31/03/2021	Preceding 3 Months Ended 31/12/2020	Corsp. 3 months ended 31/03/2020	3/31/2021	3/31/2020
	Audited	Unaudited	Audited	Audited	Audited
I Revenue from Operations			24.20	1.30	143.19
II Other Income	3.85	3.74	5.20	14.77	15.82
III Total Revenue (I+II)	3.85	3.74	29.40	16.07	159.01
IV Expenses					
Cost of Material Consumed	-	-	3.03	0.19	22.49
Employee benefits expense	0.78	8.12	46.34	34.97	139.96
Depreciation and Amortisation expense	0.21	0.32	0.70	1.21	1.63
Other Expenses	5.90	14.21	27.27	59.86	200.20
Total Expenses	6.89	22.65	77.34	96.23	364.28
V Profit/(Loss) from before Exceptional Items and tax (I-IV)	(3.04)	(18.91)	(47.94)	(80.16)	(205.27)
VI Exceptional Items	-	-	-	-	-
VII Profit/(Loss) before tax (V-VI)	(3.04)	(18.91)	(47.94)	(80.16)	(205.27)
VIII Tax Expense:					
Current Tax	-	-	-	-	-
Deferred Tax	(2.49)	-	(7.11)	(2.49)	(7.11)
IX Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(0.55)	(18.91)	(40.83)	(77.67)	(198.16)
X Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XI Tax Expense of discontinuing operations	-	-	-	-	-
XII Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)	-	-	-	-	-
XIII Profit/ (Loss) for the period (IX+XII)	(0.55)	(18.91)	(40.83)	(77.67)	(198.16)
XIV Other Comprehensive Income					
A) (i) Items that will not be reclassified to profit or loss (ii) Income Tax related to items that will not be reclassified to profit or loss					
B) (i) Items that will be reclassified to profit or loss (ii) Income Tax relating to items that will be reclassified to profit or loss	14.08	-	1.85	14.08	1.85
XV Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	13.53	(18.91)	(38.98)	(63.58)	(196.31)
XVI Comprehensive Income attributable to Non Controlling Interest	-	-	-	(0.33)	(4.45)
XVII Comprehensive Income attributable to Owners of the company	13.53	(18.91)	(38.98)	(63.24)	(191.86)
XVIII Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)					
1) Basic	0.09	(0.13)	(0.26)	(0.43)	(1.31)
2) Diluted	0.09	(0.13)	(0.26)	(0.43)	(1.31)
XIX Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)					
1) Basic	-	-	-	-	-
2) Diluted	-	-	-	-	-
XX Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)					
1) Basic	0.09	(0.13)	(0.26)	(0.43)	(1.31)
2) Diluted	0.09	(0.13)	(0.26)	(0.43)	(1.31)
XXI Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1,480.87	1,480.87	1,480.87	1,480.87	1,480.87




Notes:

1. In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013, the above Financial Results have been audited by the Statutory Auditors of Company and recommended by Audit Committee and subsequently approved by Board of Directors of Company at their meeting held on Tuesday, June 29th, 2021.
2. The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS prescribed under Section 133 of Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended).
3. The Consolidated Financial Results includes the results of the Company and its Subsidiary - Krisani Bio Sciences Private Limited.
4. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison.
5. The figures of the current quarter ended March 31, 2021 and the quarter ended March 31, 2020 are the balancing figures between the audited figures in respect of the full financial year ended respectively and published unaudited year to date figures upto the third quarter of the respective financial years.
6. The Company has only one reportable segment i.e., **Health Care** Sector. Hence, the separate disclosure on Segment information is not required.
7. The results are also available on the website of the Company www.drhsl.com

For DR HABEEBULLAH LIFE SCIENCES LIMITED


K Krishnam Raju
Executive Chairman(DIN 00874650)




Place : Hyderabad
Date: 29/06/2021

DR Habeebullah Life Sciences Limited		
Consolidated Statement of Assets and Liabilities		
<i>(INR. in Lakhs)</i>		
Particulars	CONSOLIDATED	
	31/03/2021	31/03/2020
ASSETS		
1 Non Current Assets		
a Property, Plant and Equipments	5.59	13.19
b Capital Work In Progress	-	-
c Investment Prpoerty	-	-
d Goodwill	-	-
e Other Intangible Assets	-	-
f Intangible Assets under development	1,939.78	1,899.26
g Biological assets other than bearer plants	-	-
h Financial Assets:	-	-
i Investments	0.75	0.75
ii Trade Receivables	-	-
iii Loans	-	-
iv Others	203.99	204.28
v Loans	-	-
vi Others	-	-
i Deferred Tax Assets (net)	48.59	46.10
j Other Non Current Assets	-	-
Total Non Current Assets	2,198.70	2,163.57
2 Current Assets		
a Inventories	12.92	13.11
b Financial Assets	-	-
i Investments	-	-
ii Trade Receivables	214.26	217.51
iii Cash and Cash Equivalents	1.32	2.94
iv Bank balances other than above	-	-
v Loans	94.00	94.00
vi Other financial assets	37.77	24.10
c Current Tax Assets (net)	-	-
d Other Current Assets	306.04	305.97
Total Current Assets	666.31	657.65
Total Assets	2,865.01	2,821.22
EQUITY AND LIABILITIES		
1 Equity		
a Equity Share Capital	1,480.87	1,480.87
b Other Equity	-	-
i Share Warrants	-	-
ii Reserves and Surplus	(365.81)	(302.56)
iii Non-Controlling Interests	400.21	400.55
Total - Equity	1,515.28	1,578.86



2 Liabilities		
Non Current Liabilities		
a Financial Liabilities	-	-
i Borrowings	-	-
ii Trade Payables	-	-
iii Other Financial Liabilities	-	-
b Provisions	4.56	14.50
c Deferred Tax Liabilities (net)	-	-
d Other Non Current Liabilities	-	-
Total Non Current Liabilities	4.56	14.50
Current Liabilities		
a Financial Liabilities		
i Borrowings	939.46	858.40
ii Trade Payables	28.72	30.50
iii Other Financial Liabilities		-
b Other Current Liabilities	376.98	336.53
c Provisions	-	2.43
d Current Tax Liabilities (net)	-	-
Total Current Liabilities	1,345.16	1,227.86
Total - Equity and Liabilities	2,865.01	2,821.22

For DR HABEEBULLAH LIFE SCIENCES LIMITED




Place: Hyderabad
Date: 29/06/2021

K. Krishnam Raju
Executive Chairman (DIN 00874650)

DR HABEEBULLAH LIFE SCIENCES LIMITED
 2-5-36/CLRD/1, Survey No. 36, Chintalmet X Roads, Upparapally, Attapur
 Rajendra Nagar Mandal, Hyderabad 500048, Telangana State, INDIA

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31st MARCH, 2021

	(Amount in Rs.)	
PARTICULARS	Year Ended March 31, 2021	Year Ended March 31, 2020
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	(6,288,573)	(18,716,742)
Adjustment for:		
Depreciation and Amortisation	96,014	108,374
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	(6,192,559)	(18,608,368)
Movements in Working Capital::		
(Increase)/ Decrease in trade receivables	325,722	371,574
(Increase)/ Decrease in Short Term Loans and Advances	-	-
(Increase)/ Decrease in other Current Assets	(7,173)	(7,189,718)
(Increase)/ Decrease in other other financial Assets	(1,366,531)	(1,423,643)
(Increase)/ Decrease in Inventories	19,273	280,777
Increase / (Decrease) in Trade Payables	(177,649)	650,690
Increase / (Decrease) in Other current liabilities	5,195,363	15,010,500
Increase / (Decrease) in Current Provisions	(242,944)	166,566
Change in Working Capital	3,746,061	7,866,746
Changes in non current assets and liabilities		
Decrease / (Increase) in loans & advances	29,000	(173,448)
(Decrease) / Increase in Long Term Borrowings	-	-
(Decrease) / Increase in Long Term Provisions	(993,399)	192,298
Changes in non current assets and liabilities	(964,399)	18,850
Cash Generated From Operations	(3,410,897)	(10,722,772)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(3,410,897)	(10,722,772)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increase) / Decrease in Fixed assets and Capital Work In progress	(2,272,849)	(8,867,047)
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Net cash used in Investing activities (B)	(2,272,849)	(8,867,047)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	15,000,000
Increase / (Decrease) in Borrowings	5,490,000	4,675,000
Interest paid	-	-
Net cash Flow from Financing Activities (C)	5,490,000	19,675,000
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	(193,745)	85,181
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	235,061	149,880
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	41,317	235,061

for and on behalf of the Board
 for DR HABEEBULLAH LIFE SCIENCES LIMITED

(K. Krishnam Raju)

Whole-time Director & Chairman

DIN: 00874650

DR HABEEBULLAH LIFE SCIENCES LIMITED
 2-5-36/CLRD/1, Survey No. 36, Chintalmet X Roads, Upparapally, Attapur
 Rajendra Nagar Mandal, Hyderabad 500048, Telangana State, INDIA

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31st MARCH, 2020


(Amount in Rs.)

PARTICULARS	Year Ended March 31, 2021	Year Ended March 31, 2020
A. CASH FLOW FROM OPERATING ACTIVITIES :		
Net profit before tax	(6,607,327)	(20,527,313)
<u>Adjustment for:</u>		
Depreciation and Amortisation	120,559	163,064
Interest Expenses	-	-
Interest Earned	-	-
Cash Flows from Operations before changes in assets and liabilities	(6,486,768)	(20,364,249)
<u>Movements in Working Capital::</u>		
(Increase)/ Decrease in trade receivables	325,722	371,574
(Increase) / Decrease in Short term Loans and Advances	-	-
(Increase)/Decrease in other financial assets Assets	(1,366,531)	(1,423,643)
(Increase)/Decrease in other Current Assets	(7,174)	(7,192,416)
(Increase) / Decrease in Inventories	19,270	280,779
Increase / (Decrease) in Trade Payables	(177,648)	650,689
Increase/(Decrease) in Other current liabilities	4,044,946	16,851,318
Increase/(Decrease) in Current Provisions	(242,943)	166,565
Change in Working Capital	2,595,642	9,704,866
<u>Changes in non current assets and liabilities</u>		
Decrease/(Increase) in loans & advances	29,000	(173,448)
(Decrease)/Increase in Long Term Provisions	(993,399)	377,157
Changes in non current assets and liabilities	(964,399)	203,709
<u>Cash Generated From Operations</u>	(4,855,525)	(10,455,674)
Less: Taxes paid	-	-
Net Cash from operating activities(A)	(4,855,525)	(10,455,674)
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Increase) / Decrease in Fixed assets and Capital Work In progress	(3,413,003)	(11,139,900)
Bank Balances not considered as Cash and Cash equivalents	-	-
Investment in equity Shares	-	-
Net cash used in Investing activities (B)	(3,413,003)	(11,139,900)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Increase / (Decrease) in Share Capital	-	15,000,000
Increase / (Decrease) in Borrowings	8,106,000	6,660,000
Interest paid	-	-
Net cash Flow from Financing Activities (C)	8,106,000	21,660,000
Net Increase/(Decrease) in cash & cash equivalents [A+B+C]	(162,528)	64,426
CASH & CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	294,414	229,988
CASH & CASH EQUIVALENTS AT THE END OF THE YEAR	131,885	294,414

for and on behalf of the Board
 for DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju
 Whole-time Director & Chairman
 DIN: 00874650



To,

Date: 29.06.2021

1.BSE Limited P.J. Towers, Dalal Street, Mumbai – 400001	2.Metropolitan Stock Exchange of India Limited Vibgyor Towers, 4 th floor, Plot No. C62, Opp. Trident Hotel, BandraKurla Complex, Bandra (E), Mumbai- 400098
--	---

Dear Sir/Madam,



Sub: Declaration pursuant to regulation 33(3)(d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

I, K. Krishnam Raju, Chairman & Whole-time Director of Dr Habeebullah Life Sciences Limited hereby declare that the statutory Auditors of the company, M/s. A.M. Reddy & D.R. Reddy., Chartered Accountants have issued an Audit Report with unmodified/unqualified opinion on Audited Financial Results of the company (both standalone and consolidated) for the quarter and year ended 31st March, 2021.

This declaration is issued in compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Yours sincerely,

For Dr Habeebullah Life Sciences Limited



K. Krishnam Raju
Chairman & Whole-time Director
DIN: 00874650

Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

Regd. Off : 2-5-36/CLRD/1, Chintalmet X Roads, Upperpally, Rajendra Nagar Mandal, Hyderabad-500048. TS. India.

Corp Off : No.11, Phase I, Vasudeva's Bloomfield Elation, Khajaguda, Nanakramguda, Hyderabad-500008. TS. India.

CIN No.: L85110TG1996PLC099198.

Email: cs@drhsl.com, info@drhsl.com, pcproductsindia@gmail.com

Contact No.: 040 - 2970 3333, +91 9030057370.

Website : www.drhsl.com



A.M. REDDY & D.R. REDDY

CHARTERED ACCOUNTANTS

Independent Auditor's Report on Quarterly Standalone Financial Results and Year to Date Standalone Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

To the Board of Directors of Dr Habeebullah Life Sciences Limited

Report on the Audit of Standalone Financial Results

Opinion


We have audited the accompanying standalone annual financial results of **Dr Habeebullah Life Sciences Limited** (hereinafter referred to as 'the Company') for the quarter and year ended March 31, 2021 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of net loss and other financial information of the Company for the year ended March 31, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.



We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Standalone Financial Results

This Statement has been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.


In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.


As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters



The Statement include the results for the quarter ended March 31, 2021 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our Opinion is not modified in respect of the above matter.

For A.M REDDY & D.R REDDY

Chartered Accountants

ICAI Firm Registration No. 0090685

D.Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: 21209211AAAABN2376

Place: Hyderabad

Date: June 29, 2021



A.M. REDDY & D.R. REDDY

CHARTERED ACCOUNTANTS

Independent Auditor's Report on Quarterly Consolidated Financial Results and Year to Date Consolidated Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

To the Board of Directors of Dr Habeebullah Life Sciences Limited [Holding Company]

Report on the Audit of Consolidated Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Dr Habeebullah Life Sciences Limited (hereinafter referred to as the 'Holding Company') and its subsidiary (Holding Company and its subsidiary together referred to as "the Group"), for the quarter and year ended March 31, 2021, ('the Statement') attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditor on separate audited financial statements, of the subsidiary, the aforesaid Statement:

(i) include the annual financial results of the following entity


Sr. No	Name of the Entity	Relationship with the Holding Company
1	Krisani Bio Sciences Private Limited	Subsidiary

(ii) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(iii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India, of net loss and other financial information of the Group for the year ended March 31, 2021.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the



provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Consolidated Financial Results

These Statement have been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss and other comprehensive income and other financial information of the Group in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.


In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.


As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters


1. The Statement include the audited Financial Results of aforesaid subsidiary, whose Financial Statements reflect Group's share of total assets (before consolidation adjustment) of Rs. 16,69,53,612 as at March 31, 2021, Group's share of total revenue (before consolidation adjustment) is Nil and Group's share of total net loss after tax (before consolidation adjustment) of Rs. 69,652 for the year ended March 31,2021 as considered in the Statement, which have been audited by another independent auditors. The independent auditors' reports on financial statements of this subsidiary have been furnished to us and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.
2. The Statement include the results for the quarter ended March 31, 2021 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Our opinion is not modified in respect of the above matters.

For A.M REDDY & D.R REDDY

Chartered Accountants

ICAI Firm Registration No. 0090685



D.Rama Krishna Reddy

Partner

Membership No. 209211

UDIN: 21209211AAAAB06785

Place: Hyderabad

Date: June 29, 2021

